Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.49 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10702682 | 0.89 | CYP19A1 (0.41) | CYP19A1UGT1A4PDE4DACHEESR1 | |
| SCHEMBL10187411 | 0.87 | CYP19A1 (0.40) | CYP19A1UGT1A4PDE4D | |
| SCHEMBL17124419 | 0.84 | CYP19A1 (0.38) | CYP19A1UGT1A4PDE4D | |
| SCHEMBL3173073 | 0.83 | CYP19A1 (0.49) | CYP19A1UGT1A4PDE4DESR1ESR2 | |
| SCHEMBL28381262 | 0.83 | CYP19A1 (0.51) | CYP19A1UGT1A4PDE4DESR1ESR2 | |
| SCHEMBL24317094 | 0.81 | ATM (0.42) | CYP19A1UGT1A4PDE4DESR1ESR2 | |
| SCHEMBL13265761 | 0.81 | CYP19A1 (0.54) | CYP19A1UGT1A4PDE4DESR1ESR2 | |
| SCHEMBL4246221 | 0.81 | HTT (0.38) | CYP19A1UGT1A4PDE4D | |
| SCHEMBL12123247 | 0.79 | CYP19A1 (0.49) | CYP19A1UGT1A4PDE4DESR1ESR2 | |
| SCHEMBL18983725 | 0.79 | ESR1 (0.46) | CYP19A1UGT1A4PDE4DESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008034644-A2 | PROCESS FOR MAKING ANASTROZOLE | SYNTHON B.V. (NL) | 2008-03-27 | — | — | WO | claimed |
| US-20080076933-A1 | PROCESS FOR MAKING ANASTROZOLE | SYNTHON BV (NL) | 2008-03-27 | — | — | US | claimed |
| EP-2024343-B1 | PROCESS FOR PURIFICATION OF ANASTROZOLE | SYNTHON BV (NL) | 2015-09-09 | — | — | EP | disclosed |
| US-8470860-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2013-06-25 | — | — | US | disclosed |
| US-8470860-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2013-06-25 | — | — | US | disclosed |
| US-20120015919-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND ESTROGEN RECEPTOR ANTAGONISTS | TRAGARA PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110021586-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX, LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-20110021586-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX, LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-7763642-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LTD. (GB) | 2010-07-27 | — | — | US | disclosed |
| US-7763642-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LTD. (GB) | 2010-07-27 | — | — | US | disclosed |
| US-7655806-B2 | Process for purification of anastrozole | SYNTHON BV (NL) | 2010-02-02 | — | — | US | disclosed |
| US-20070281982-A1 | PROCESS FOR PURIFICATION OF ANASTROZOLE | SYNTHON BV (NL) | 2007-12-06 | — | — | US | disclosed |
| WO-2007134846-A2 | PROCESS FOR PURIFICATION OF ANASTROZOLE | SYNTHON B.V. (NL) | 2007-11-29 | — | — | WO | disclosed |
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2007-05-24 | — | — | US | disclosed |
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2007-05-24 | — | — | US | disclosed |
| WO-2007039913-A1 | PROCESS FOR THE PREPARATION OF 2,2’-[5-(1,2,4-TRIAZOLE-1-YLMETHYL) -1,3-PHENYLENE] DI (2-METHYLPROPIONITRILE). | USV LIMITED (IN) | 2007-04-12 | — | — | WO | disclosed |
| US-RE36617-E | Anastrozole and salts as anticancer agent | ZENECA LIMITED (GB) | 2000-03-14 | — | — | US | disclosed |
| EP-0296749-B1 | (Substituted aralkyl) heterocyclic compounds | ZENECA LTD (GB) | 1994-10-26 | — | — | EP | disclosed |
| US-4935437-A | (Substituted aralkyl) heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-19 | — | — | US | disclosed |
| EP-0296749-A1 | (Substituted aralkyl) heterocyclic compounds | ZENECA LIMITED (GB) | 1988-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | CYP19A1, CYP17A1, CYP21A2 | CYP19A1 1/4885UGT1A4 270/4885PDE4D 3642/4885 |
| US-20070281982-A1 | PROCESS FOR PURIFICATION OF ANASTROZOLE | CYP19A1, HSD17B11, ADH1A | CYP19A1 1/4885UGT1A4 254/4885PDE4D 1560/4885 |
| US-20120015919-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND ESTROGEN RECEPTOR ANTAGONISTS | PTGER2, PTGES2, PTGS2 | CYP19A1 9/4885UGT1A4 1030/4885PDE4D 2260/4885 |
| US-20080076933-A1 | PROCESS FOR MAKING ANASTROZOLE | CYP19A1, CYP3A4, CYP2C19 | CYP19A1 1/4885UGT1A4 47/4885PDE4D 1598/4885 |
| US-20110021586-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | CYP19A1, CYP17A1, CYP21A2 | CYP19A1 1/4885UGT1A4 270/4885PDE4D 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.